AIkido Pharma - AIKI Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AIkido Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AIKI shares.
View AIKI analyst ratings or view top-rated stocks.

1 brokers have issued 1-year price targets for AIkido Pharma's stock. Their AIKI share price forecasts range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 353.3% from the stock's current price.
View analysts price targets for AIKI or view top-rated stocks among Wall Street analysts.

AIkido Pharma's stock was trading at $9.9790 at the start of the year. Since then, AIKI stock has decreased by 64.6% and is now trading at $3.53.
View the best growth stocks for 2022 here.

AIkido Pharma saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 65,200 shares, a drop of 12.7% from the October 31st total of 74,700 shares. Based on an average trading volume of 76,700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.3% of the company's shares are short sold.
View AIkido Pharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our AIKI earnings forecast.

AIkido Pharma Inc. (NASDAQ:AIKI) issued its quarterly earnings data on Thursday, November, 10th. The business services provider reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by $0.40.

Shares of AIkido Pharma reverse split on the morning of Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), Nuwellis (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV).

AIkido Pharma trades on the NASDAQ under the ticker symbol "AIKI."

AIkido Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.53%), Two Sigma Advisers LP (1.58%), Dimensional Fund Advisors LP (1.05%), Two Sigma Investments LP (0.98%), Equitec Proprietary Markets LLC (0.36%) and Jane Street Group LLC (0.20%). Insiders that own company stock include Anthony Hayes, Kyle Michael Wool and Soo Yu.
View institutional ownership trends.

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AIKI stock can currently be purchased for approximately $3.53.

AIkido Pharma (NASDAQ:AIKI) has a market capitalization of $19.38 million and generates $10,000.00 in revenue each year. The business services provider earns $-7,170,000.00 in net income (profit) each year or ($3.8805) on an earnings per share basis.

AIkido Pharma's mailing address is ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020. The official website for the company is www.spherix.com. The business services provider can be reached via phone at (112) 745-1374, via email at investorrelations@spherix.com, or via fax at 703-992-9348.